PURPOSE: In this study, we introduce a methodology for preparing 18F-labeled Affibody protein, specifically 18F-Anti-HER2 dimeric Affibody (14 kDa), for in vivo imaging of HER2neu with positron emission tomography (PET). PROCEDURES: We have used 4-[18F]fluorobenzaldehyde as a synthon to prepare 18F-Anti-HER2 Affibody. Aminooxy-functionalized Affibody (Anti-HER2-ONH2) was incubated with 4-[18F]fluorobenzaldehyde in ammonium acetate buffer at pH 4 in the presence of methanol at 70 degrees C for 15 min. The resulting 18F-labeled Affibody molecule was evaluated as a PET probe in xenograft models expressing HER2. RESULTS: We have successfully prepared 18F-Anti-HER2 dimeric Affibody (14 kDa), N-(4-[18F]fluorobenzylidine)oxime-Anti-HER2 Affibody, [18F]FBO-Anti-HER2, in 26-30% radiochemical yields (decay corrected). High-contrast small-animal PET images with relatively moderate tumor uptake (1.79 +/- 0.40% ID/g) were observed for the 18F-Anti-HER2 Affibody. CONCLUSION: Site-specific 18F-labeled Affibody against HER2 has been synthesized via chemoselective oxime formation between an aminooxy-functionalized Affibody and 18F-fluorobenzaldehyde. The results have implications for radiolabeling of other affibodies and macromolecules and should also be important for advancing Affibody imaging with PET.
PURPOSE: In this study, we introduce a methodology for preparing 18F-labeled Affibody protein, specifically 18F-Anti-HER2 dimeric Affibody (14 kDa), for in vivo imaging of HER2neu with positron emission tomography (PET). PROCEDURES: We have used 4-[18F]fluorobenzaldehyde as a synthon to prepare 18F-Anti-HER2 Affibody. Aminooxy-functionalized Affibody (Anti-HER2-ONH2) was incubated with 4-[18F]fluorobenzaldehyde in ammonium acetate buffer at pH 4 in the presence of methanol at 70 degrees C for 15 min. The resulting 18F-labeled Affibody molecule was evaluated as a PET probe in xenograft models expressing HER2. RESULTS: We have successfully prepared 18F-Anti-HER2 dimeric Affibody (14 kDa), N-(4-[18F]fluorobenzylidine)oxime-Anti-HER2 Affibody, [18F]FBO-Anti-HER2, in 26-30% radiochemical yields (decay corrected). High-contrast small-animal PET images with relatively moderate tumor uptake (1.79 +/- 0.40% ID/g) were observed for the 18F-Anti-HER2 Affibody. CONCLUSION: Site-specific 18F-labeled Affibody against HER2 has been synthesized via chemoselective oxime formation between an aminooxy-functionalized Affibody and 18F-fluorobenzaldehyde. The results have implications for radiolabeling of other affibodies and macromolecules and should also be important for advancing Affibody imaging with PET.
Authors: Anna Orlova; Mikaela Magnusson; Tove L J Eriksson; Martin Nilsson; Barbro Larsson; Ingmarie Höidén-Guthenberg; Charles Widström; Jörgen Carlsson; Vladimir Tolmachev; Stefan Ståhl; Fredrik Y Nilsson Journal: Cancer Res Date: 2006-04-15 Impact factor: 12.701
Authors: Torun Engfeldt; Thuy Tran; Anna Orlova; Charles Widström; Joachim Feldwisch; Lars Abrahmsen; Anders Wennborg; Amelie Eriksson Karlström; Vladimir Tolmachev Journal: Eur J Nucl Med Mol Imaging Date: 2007-06-13 Impact factor: 9.236
Authors: Tatsushi Toyokuni; Joseph C Walsh; Alan Dominguez; Michael E Phelps; Jorge R Barrio; Sanjiv S Gambhir; Nagichettiar Satyamurthy Journal: Bioconjug Chem Date: 2003 Nov-Dec Impact factor: 4.774
Authors: Zheng Miao; Gang Ren; Lei Jiang; Hongguang Liu; Jack M Webster; Rong Zhang; Mohammad Namavari; Sanjiv S Gambhir; Faisal Syud; Zhen Cheng Journal: Eur J Nucl Med Mol Imaging Date: 2011-07-15 Impact factor: 9.236
Authors: Zhen Cheng; Omayra Padilla De Jesus; Daniel J Kramer; Abhijit De; Jack M Webster; Olivier Gheysens; Jelena Levi; Mohammad Namavari; Sen Wang; Jinha Mark Park; Rong Zhang; Hongguang Liu; Brian Lee; Faisal A Syud; Sanjiv Sam Gambhir Journal: Mol Imaging Biol Date: 2009-09-25 Impact factor: 3.488
Authors: Gang Ren; Rong Zhang; Zhe Liu; Jack M Webster; Zheng Miao; Sanjiv S Gambhir; Faisal A Syud; Zhen Cheng Journal: J Nucl Med Date: 2009-08-18 Impact factor: 10.057
Authors: Mohammad Namavari; Zhen Cheng; Rong Zhang; Abhijit De; Jelena Levi; Joshua K Hoerner; Shahriar S Yaghoubi; Faisal A Syud; Sanjiv S Gambhir Journal: Bioconjug Chem Date: 2009-03-18 Impact factor: 4.774